What is claimed is:

1. A method of treating, preventing, or delaying development or progression of prostate cancer comprising:

providing an antibody or antigen binding portion thereof which binds to an antigen expressed on the surface of prostate epithelial cells, said antigen including the epitope bound by an antibody of deposit HB11892, wherein the antibody is an IgG which binds viable cells and wherein the antibody or antigen binding portion thereof is conjugated to a cytotoxic drug; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat, prevent, or delay the development or progression of prostate cancer.

2. The method according to claim 1, wherein the prostate cancer is metastatic.

3. The method according to claim 2, wherein the metastatic prostate cancer involves a bone marrow or a lymph node metastasis.

4. The method according to claim 1, wherein the administering is carried out parenterally.

5. The method according to claim 4, wherein the administering is carried out intravenously.

6. The method according to claim 1, wherein the administering is carried out by intracavitary

instillation.

7. The method according to claim 1, wherein the antibody or antigen binding portion thereof is administered following a prostatectomy.

8. The method according to claim 1, wherein the antibody is a monoclonal antibody.

9. The method according to claim 1, wherein the antibody or antigen binding portion thereof is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment.

10. The method according to claim 1, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation, molecules of plant, fungal, or bacterial origin, biological proteins, and mixtures thereof.

11. The method according to claim 1, wherein the cytotoxic drug is a compound emitting radiation.

12. The method according to claim 1, wherein the cytotoxic drug is a molecule of bacterial origin.

13. The method according to claim 1, wherein the cytotoxic drug is a molecule of plant origin.

14. The method according to claim 1, wherein the antibody or antigen binding portion thereof is in a composition further comprising a pharmaceutically acceptable carrier,

excipient, or stabilizer.

15. The method according to claim 1, wherein the antibody or antigen binding portion thereof is administered in conjunction with a second therapeutic modality.

16. The method according to claim 15, wherein the second therapeutic modality is selected from the group consisting of surgery, radiation, chemotherapy, immunotherapy and hormone replacement.